サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1501049

高脂血症治療薬の世界市場

Hyperlipidemia Drugs

出版日
ページ情報
英文 94 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
高脂血症治療薬の世界市場
出版日: 2024年06月26日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 94 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

高脂血症治療薬の世界市場は2030年までに381億米ドルに達する見込み

2023年に214億米ドルと推定される高脂血症治療薬の世界市場は、分析期間2023-2030年にCAGR 8.6%で成長し、2030年には381億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるスタチン薬剤クラス別は、CAGRマイナス6%を記録し、分析期間終了時には35億米ドルに達すると予測されます。PCSK9阻害剤薬剤クラス別セグメントは、今後7年間のCAGRが24.8%と予測されます。

米国市場は58億米ドル、中国はCAGR 18.1％で成長すると予測

米国の高脂血症治療薬市場は、2023年には58億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに115億米ドルの市場規模に達すると予測され、分析期間2023年から2030年までのCAGRは18.1%です。その他の注目すべき地域市場としては、日本とカナダがあり、それぞれ2023年から2030年にかけて2.4%と4.6%の成長が予測されています。欧州では、ドイツがCAGR約3%で成長すると予測されています。オーストラリア、インド、韓国などの国々が牽引するアジア太平洋市場は、2030年までに61億米ドルに達すると予測されます。

2024年向け新レポートの特徴

  • インフルエンサーのエンゲージメント統計へのフルアクセス
  • デジタルアーカイブと"MarketGlass"リサーチプラットフォームへの無料アクセス。当社独自のMarketGlassプラットフォームは、世界中の専門家の創造性と市場知識を統合的かつコラボレーティブに提供します。当社の最新鋭ツールは、参加者のプライバシーとアイデンティティを保護しながら、世界クラスの市場展望をもたらします。本レポートに掲載されている数字、統計、市場に関する説明は、この分野の専門家やインフルエンサーによって共有された、完全に精査された洞察に基づいています。
  • リアルタイムのデータシミュレーター・ツールや特注のレポート作成機能を備えたインタラクティブなアンケートに参加できます。
  • 企業間のスマートな意見交換のためのピアコラボレーティブ・インタラクティブプラットフォームへのフルクライアントアクセス
  • 1年間の無料レポート更新
  • 主要企業の世界市場シェアを含む競合カバレッジ
  • 複数の地域にまたがる企業の市場プレゼンス分析（好調/活発/ニッチ/マイナー）
  • 専門家/インフルエンサーのインタビュー、ポッドキャスト、プレス発表、イベント基調講演のYouTubeビデオへのアクセス

2024年の世界経済に期待すること

金融引き締めとそれに伴う金利上昇による地政学的な影響と経済的不安定が、2024年の世界経済を波乱に満ちたものにすると思われます。中東での敵対行為や、ますます頻発する気候災害など、いくつかの要因が回復への道筋に圧力をかけ続けると思われます。リスクの一方で、ディスインフレの兆候が強まり、頑迷なインフレに対する不安が緩和され、サプライチェーンが正常化し、エネルギーコストの変動にもかかわらず物価が緩やかになるなど、いくつかのプラス材料も具体化しつつあります。インドや米国をはじめとするG21諸国の選挙は、資本の流れや投資戦略に影響を与える可能性があります。インドが世界な投資先として注目される一方で、米国を拠点とするハイテク企業は、才能と資本のダイナミックなエコシステムに後押しされ、引き続き優位を保つと思われます。シリコンバレーをはじめとするハイテク機会は、国内経済が減速しているとはいえ底堅く、規制環境も整備されていることから、高成長の可能性を求める投資家にとって引き続き魅力的です。欧州は金融引き締め政策と景気後退リスクとの戦いが続くが、英国は見通しが最も厳しく、2024年の景気後退リスクが最も高いです。中国は、政府支出と個人消費の改善に支えられた成長が期待されるもの、引き続きワイルドカードとなります。不安定な環境は、投資家にも企業にもチャンスと課題の両方をもたらすと思われます。成長への触媒としてボラティリティを受け入れるとともに、敏捷性と戦略的な先見性をもって投資判断に臨むことが、生き残りのために重要であることに変わりはないです。

調査対象企業の例（全43件）

  • Amgen Inc.
  • AstraZeneca
  • Daiichi Sankyo Company Ltd.
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly & Company
  • Esperion Therapeutics, Inc.
  • Formac Pharmaceuticals N.V.
  • GlaxoSmithKline Pharmaceuticals Limited
  • Immuron Limited
  • Isis Pharmaceuticals, Inc.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP22005

Global Hyperlipidemia Drugs Market to Reach $38.1 Billion by 2030

The global market for Hyperlipidemia Drugs estimated at US$21.4 Billion in the year 2023, is expected to reach US$38.1 Billion by 2030, growing at a CAGR of 8.6% over the analysis period 2023-2030. Statins Drug Class, one of the segments analyzed in the report, is expected to record a -6% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the PCSK9 Inhibitors Drug Class segment is estimated at 24.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $5.8 Billion, While China is Forecast to Grow at 18.1% CAGR

The Hyperlipidemia Drugs market in the U.S. is estimated at US$5.8 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$11.5 Billion by the year 2030 trailing a CAGR of 18.1% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.4% and 4.6% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 3% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.1 Billion by the year 2030.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 43 Featured) -

  • Amgen Inc.
  • AstraZeneca
  • Daiichi Sankyo Company Ltd.
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly & Company
  • Esperion Therapeutics, Inc.
  • Formac Pharmaceuticals N.V.
  • GlaxoSmithKline Pharmaceuticals Limited
  • Immuron Limited
  • Isis Pharmaceuticals, Inc.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Hyperlipidemia Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Hyperlipidemia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Hyperlipidemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Statins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Statins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Statins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for PCSK9 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for PCSK9 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for PCSK9 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Cholesterol Absorption Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Cholesterol Absorption Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Cholesterol Absorption Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Bile Acid Sequestrants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Bile Acid Sequestrants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Bile Acid Sequestrants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Fibric Acid Derivatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Fibric Acid Derivatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Fibric Acid Derivatives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Hyperlipidemia Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hyperlipidemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • JAPAN
    • Hyperlipidemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • CHINA
    • Hyperlipidemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: China 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • EUROPE
    • Hyperlipidemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Hyperlipidemia Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Europe 16-Year Perspective for Hyperlipidemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • FRANCE
    • Hyperlipidemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 44: France Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: France Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: France 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • GERMANY
    • Hyperlipidemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 47: Germany Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Germany Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Germany 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Italy Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Italy 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Hyperlipidemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 53: UK Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: UK Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: UK 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 56: Spain Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Spain Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Spain 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 59: Russia Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Russia Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Russia 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Rest of Europe Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Rest of Europe 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Hyperlipidemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 66: Asia-Pacific Historic Review for Hyperlipidemia Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Asia-Pacific 16-Year Perspective for Hyperlipidemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Asia-Pacific Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Asia-Pacific 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Hyperlipidemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 71: Australia Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Australia Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Australia 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • INDIA
    • Hyperlipidemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 74: India Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: India Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: India 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 77: South Korea Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: South Korea Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: South Korea 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 80: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Asia-Pacific Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Rest of Asia-Pacific 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Hyperlipidemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 83: Latin America Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 84: Latin America Historic Review for Hyperlipidemia Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Latin America 16-Year Perspective for Hyperlipidemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 86: Latin America Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Latin America Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Latin America 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 89: Argentina Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Argentina Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Argentina 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 92: Brazil Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Brazil Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Brazil 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 95: Mexico Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Mexico Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Mexico 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 98: Rest of Latin America Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Latin America Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Latin America 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Hyperlipidemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 101: Middle East Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 102: Middle East Historic Review for Hyperlipidemia Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Middle East 16-Year Perspective for Hyperlipidemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 104: Middle East Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Middle East Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Middle East 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 107: Iran Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Iran Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Iran 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 110: Israel Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Israel Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Israel 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 113: Saudi Arabia Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Saudi Arabia Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Saudi Arabia 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 116: UAE Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UAE Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UAE 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 119: Rest of Middle East Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Middle East Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Middle East 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030
  • AFRICA
    • Hyperlipidemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 122: Africa Recent Past, Current & Future Analysis for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Africa Historic Review for Hyperlipidemia Drugs by Drug Class - Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Africa 16-Year Perspective for Hyperlipidemia Drugs by Drug Class - Percentage Breakdown of Value Sales for Statins, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Bile Acid Sequestrants, Fibric Acid Derivatives, Combination and Other Drug Classes for the Years 2014, 2024 & 2030

IV. COMPETITION